Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection: A Multi-Arm Multi-Stage Randomized Trial (MAMS) to Evaluate the Effectiveness of Several Specific Treatments in Reducing the Risk of Clinical Worsening or Death in Sub-Saharan Africa (COVERAGE-Africa)

Marcy et al., NCT04920838, COVERAGE-A, NCT04920838

Aug 2023

Source PDF All Studies Meta AnalysisMeta

Estimated 600 patient budesonide early treatment RCT with results expected soon (estimated completion over 2 months ago).

3 budesonide RCTs have results missing long after expected Afazeli, Korea United Pharm., Taille
The trials report a total of 316 patients, with 1 trial having actual enrollment of 146, and the remainder estimated.

Important missing comments or errors? Let us know.

This study includes nitazoxanide, budesonide, and acetaminophen.

Marcy et al., 1 Aug 2023, Randomized Controlled Trial, multiple countries, trial NCT04920838 (history) (COVERAGE-A).

Contact: olivier.marcy@u-bordeaux.fr, anthony.lhostellier@u-bordeaux.fr, armelpoda@yahoo.fr, sondoapoline@yahoo.fr.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Budesonide All

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0